Elicio Therapeutics (ELTX) Cash from Operations (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Cash from Operations for 7 consecutive years, with -$8.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 8.77% year-over-year to -$8.2 million; the trailing twelve-month figure through Jun 2026 stood at -$37.7 million (down 7.43% YoY), and the FY2025 full-year result was -$37.0 million, changed 0.31% from the prior year.
• Cash from Operations grew to -$8.2 million in Q2 2026 per ELTX's latest filing, from -$11.6 million in the prior quarter.
• Across five years, Cash from Operations topped out at $6.1 million in Q2 2022 and bottomed at -$15.7 million in Q1 2022.
• Historically, Cash from Operations has averaged -$8.3 million across 5 years, with a median of -$8.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations jumped 158.27% in 2022, then plunged 254.42% in 2023.
• Over 5 years, Cash from Operations stood at -$7.3 million in 2022, then sank by 36.0% to -$9.9 million in 2023, then gained by 11.63% to -$8.7 million in 2024, then gained by 22.27% to -$6.8 million in 2025, then declined by 20.13% to -$8.2 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$8.2 million, -$11.6 million, and -$6.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.